Cargando…

Financial toxicity in patients with lung cancer: a scoping review protocol

INTRODUCTION: Lung cancer has the second-ranked morbidity rate and the first-ranked mortality rate worldwide. With the progression of the cancer condition and the advancement of new treatments, the corresponding medical expenses have risen sharply. Nowadays, financial toxicity has become one of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Liang, Zhuang, Minling, Luo, Chengcan, Zhu, Ruiyun, Wu, Bei, Xu, Wenxia, Xu, Bo, Xu, Ruiyan, Ye, Xianghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131061/
https://www.ncbi.nlm.nih.gov/pubmed/35613746
http://dx.doi.org/10.1136/bmjopen-2021-057801
_version_ 1784713104955801600
author Fu, Liang
Zhuang, Minling
Luo, Chengcan
Zhu, Ruiyun
Wu, Bei
Xu, Wenxia
Xu, Bo
Xu, Ruiyan
Ye, Xianghong
author_facet Fu, Liang
Zhuang, Minling
Luo, Chengcan
Zhu, Ruiyun
Wu, Bei
Xu, Wenxia
Xu, Bo
Xu, Ruiyan
Ye, Xianghong
author_sort Fu, Liang
collection PubMed
description INTRODUCTION: Lung cancer has the second-ranked morbidity rate and the first-ranked mortality rate worldwide. With the progression of the cancer condition and the advancement of new treatments, the corresponding medical expenses have risen sharply. Nowadays, financial toxicity has become one of the most common concerns in patients with cancer. However, by far, the full landscape of studies on financial toxicity is unclear in patients with lung cancer. Thus, this scoping review aims to summarise the degree, affecting factors, outcomes and intervention strategies of financial toxicity in patients with lung cancer. METHODS AND ANALYSIS: This scoping review will be developed following the methodology described in the Joanna Briggs Institute Manual for Evidence Synthesis on scoping review protocol, which was based on Arksey and O’Malley’s methodological framework, Levac et al’s recommendations for applying this framework and Peters et al’s enhancements of the framework. From the day of database building to 31 December 2021, 10 English databases will be searched in the ‘Abstract’ field with three key search terms: “Lung”, “Cancer” and “Financial toxicity”. The studies’ screening and data extraction will be independently performed by two reviewers (MZ and RZ). Any disagreements between the two reviewers (MZ and RZ) will be resolved by consensus, and a third reviewer (BW) will be invited if necessary. The results will be analysed and presented using tables and figures. This scoping review will be reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. ETHICS AND DISSEMINATION: An ethical approval is not required for this scoping review protocol, nor for the scoping review. The results of this scoping review will be disseminated through publication in a peer-reviewed journal or presentation at conferences. REGISTRATION: This scoping review protocol has been registered in the Open Science Framework (https://osf.io/ub45n/?view_only=bb93eb94e1434a0f8196b3b61cffcec2).
format Online
Article
Text
id pubmed-9131061
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91310612022-06-09 Financial toxicity in patients with lung cancer: a scoping review protocol Fu, Liang Zhuang, Minling Luo, Chengcan Zhu, Ruiyun Wu, Bei Xu, Wenxia Xu, Bo Xu, Ruiyan Ye, Xianghong BMJ Open Oncology INTRODUCTION: Lung cancer has the second-ranked morbidity rate and the first-ranked mortality rate worldwide. With the progression of the cancer condition and the advancement of new treatments, the corresponding medical expenses have risen sharply. Nowadays, financial toxicity has become one of the most common concerns in patients with cancer. However, by far, the full landscape of studies on financial toxicity is unclear in patients with lung cancer. Thus, this scoping review aims to summarise the degree, affecting factors, outcomes and intervention strategies of financial toxicity in patients with lung cancer. METHODS AND ANALYSIS: This scoping review will be developed following the methodology described in the Joanna Briggs Institute Manual for Evidence Synthesis on scoping review protocol, which was based on Arksey and O’Malley’s methodological framework, Levac et al’s recommendations for applying this framework and Peters et al’s enhancements of the framework. From the day of database building to 31 December 2021, 10 English databases will be searched in the ‘Abstract’ field with three key search terms: “Lung”, “Cancer” and “Financial toxicity”. The studies’ screening and data extraction will be independently performed by two reviewers (MZ and RZ). Any disagreements between the two reviewers (MZ and RZ) will be resolved by consensus, and a third reviewer (BW) will be invited if necessary. The results will be analysed and presented using tables and figures. This scoping review will be reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. ETHICS AND DISSEMINATION: An ethical approval is not required for this scoping review protocol, nor for the scoping review. The results of this scoping review will be disseminated through publication in a peer-reviewed journal or presentation at conferences. REGISTRATION: This scoping review protocol has been registered in the Open Science Framework (https://osf.io/ub45n/?view_only=bb93eb94e1434a0f8196b3b61cffcec2). BMJ Publishing Group 2022-05-23 /pmc/articles/PMC9131061/ /pubmed/35613746 http://dx.doi.org/10.1136/bmjopen-2021-057801 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Oncology
Fu, Liang
Zhuang, Minling
Luo, Chengcan
Zhu, Ruiyun
Wu, Bei
Xu, Wenxia
Xu, Bo
Xu, Ruiyan
Ye, Xianghong
Financial toxicity in patients with lung cancer: a scoping review protocol
title Financial toxicity in patients with lung cancer: a scoping review protocol
title_full Financial toxicity in patients with lung cancer: a scoping review protocol
title_fullStr Financial toxicity in patients with lung cancer: a scoping review protocol
title_full_unstemmed Financial toxicity in patients with lung cancer: a scoping review protocol
title_short Financial toxicity in patients with lung cancer: a scoping review protocol
title_sort financial toxicity in patients with lung cancer: a scoping review protocol
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131061/
https://www.ncbi.nlm.nih.gov/pubmed/35613746
http://dx.doi.org/10.1136/bmjopen-2021-057801
work_keys_str_mv AT fuliang financialtoxicityinpatientswithlungcancerascopingreviewprotocol
AT zhuangminling financialtoxicityinpatientswithlungcancerascopingreviewprotocol
AT luochengcan financialtoxicityinpatientswithlungcancerascopingreviewprotocol
AT zhuruiyun financialtoxicityinpatientswithlungcancerascopingreviewprotocol
AT wubei financialtoxicityinpatientswithlungcancerascopingreviewprotocol
AT xuwenxia financialtoxicityinpatientswithlungcancerascopingreviewprotocol
AT xubo financialtoxicityinpatientswithlungcancerascopingreviewprotocol
AT xuruiyan financialtoxicityinpatientswithlungcancerascopingreviewprotocol
AT yexianghong financialtoxicityinpatientswithlungcancerascopingreviewprotocol